Optimizing the Use of Anti-Amyloid Therapy for Early Asymptomatic AD
Monday, July 28, 2025
9:30 AM – 10:45 AM PT simulcast
10:30 AM – 11:45 AM MT
11:30 PM – 12:45 PM CT
12:30 PM – 1:45 PM ET
Program Features
- Holographic Caregiver Avatar
- DETECT Alzheimer’s website
- Online personalized quality-improvement poster-generation portal
- DETECT Alzheimer’s Ambassador program
Program Overview
This program aims to provide clinicians with up-to-date information on treatment for early symptomatic Alzheimer’s disease (AD). Through this program, clinicians will improve their ability to summarize the risk and benefit profile of anti-amyloid therapeutics for patients with early symptomatic AD and increase their competence with facilitating multidisciplinary shared decision-making discussions with patients and caregivers that accurately describe potential benefits, risks, and associated monitoring requirements of anti-amyloid therapies. Innovative learning strategies including small group breakouts and incorporating the patient/caregiver perspective via faculty discussions with a real caregiver on stage and the use of holographic simulations at the entrance to the meeting room will reinforce these key takeaways. Our goal is to provide information that empowers clinicians to make informed treatment decisions, thereby improving the standard of care for patients with this challenging disease.
Target Audience
This program will meet the educational needs of healthcare providers involved in the diagnosis and continued care of patients with early symptomatic AD on a global level, including specialists (i.e., dementia specialists, neurologists, geriatricians, geriatric psychiatrists), nurse practitioners (NPs; working in AD specialty settings), and physicians assistants (PAs; working in AD specialty settings).
Learning Objectives
- Summarize the risk and benefit profile of anti-amyloid therapeutics for patients with early symptomatic AD
- Facilitate multidisciplinary SDM discussions with patients and caregivers that accurately describe potential benefits, risks, and associated monitoring requirements of anti-amyloid therapies
THE ACCREDITATION POLICY IS APPLICABLE TO EACH EVENT
Joint Accreditation Statement
Physician Credit Designation Statement
Med Learning Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
Nurses (ANCC) Credit Designation
Med Learning Group designates this activity for a maximum of up to 1.5 ANCC contact hours.
EACCME Credit Designation Statement
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu
Disclosure Policy Statement
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Disclosure Of Unlabeled Use
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
Disclaimer
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at info@medlearninggroup.com
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/
Americans With Disabilities Act
Event Staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to the live event at info@medlearninggroup.com
Release date: July 28, 2025
Expiration date: July 28, 2025
Estimated time to completion: 1.25 hours
